StockData
Viatris Inc logo

Viatris Inc (VTRS) stock

VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/308% below fair value
$20.45−0.29 (-1.40%)

Close on Nov 17, 2026Market cap $23.49BP/E –Yield 2.35%

Viatris r&d expenses

Research and development expenses are spending on new products and technology.

Viatris's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.02B, up 20.8% year over year. For fiscal 2025 it was $965.90M, up 19.4% from the year before. The highest annual figure on record is $965.90M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$965.90M+19.4%
FY2024Dec 31, 2024$808.70M+0.4%
FY2023Dec 31, 2023$805.20M+21.6%
FY2022Dec 31, 2022$662.20M-2.8%
FY2021Dec 31, 2021$681.00M+32.9%
FY2020Dec 31, 2020$512.60M-19.9%
FY2019Dec 31, 2019$639.90M-9.2%
FY2018Dec 31, 2018$704.50M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$248.30M+13.5%
Q1 FY2026Mar 31, 2026$248.60M+12.0%
Q4 FY2025Dec 31, 2025$274.70M+33.0%
Q3 FY2025Sep 30, 2025$250.40M+26.2%
Q2 FY2025Jun 30, 2025$218.80M+7.2%
Q1 FY2025Mar 31, 2025$222.00M+11.2%
Q4 FY2024Dec 31, 2024$206.50M+1.8%
Q3 FY2024Sep 30, 2024$198.40M-6.1%
Q2 FY2024Jun 30, 2024$204.10M-2.0%
Q1 FY2024Mar 31, 2024$199.70M+9.2%
Q4 FY2023Dec 31, 2023$202.80M+11.2%
Q3 FY2023Sep 30, 2023$211.20M+20.8%
Q2 FY2023Jun 30, 2023$208.30M+28.1%
Q1 FY2023Mar 31, 2023$182.90M+28.5%
Q4 FY2022Dec 31, 2022$182.40M-7.5%
Q3 FY2022Sep 30, 2022$174.90M+15.0%
Q2 FY2022Jun 30, 2022$162.60M+10.1%
Q1 FY2022Mar 31, 2022$142.30M-22.7%
Q4 FY2021Dec 31, 2021$197.10M+75.5%
Q3 FY2021Sep 30, 2021$152.10M+17.2%
Q2 FY2021Jun 30, 2021$147.70M-5.5%
Q1 FY2021Mar 31, 2021$184.10M+61.2%
Q4 FY2020Dec 31, 2020$112.30M–
Q3 FY2020Sep 30, 2020$129.80M–
Q2 FY2020Jun 30, 2020$156.30M–
Q1 FY2020Mar 31, 2020$114.20M–

More Viatris figures

See a number that looks wrong?